Skip to content
10-Q

Quarterly Report

SpyGlass Pharma, Inc. SGP

0001778922-26-000035

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 20, 2026 33.43M sh
Shares Diluted Q1 2026 · Mar 31, 2026 19.93M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.23M sh
Capex Q1 2026 · Mar 31, 2026 $676K
Capex Q1 2026 · Mar 31, 2025 $164K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$13.54M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.2M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $238.9M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $96.36M
Stockholders Equity Q1 2026 · Mar 31, 2026 $250.11M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$98.84M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$68.85M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$60.47M
Current Liabilities Q1 2026 · Mar 31, 2026 $6.67M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.58M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.27M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.17M
Current Assets Q1 2026 · Mar 31, 2026 $253.36M
Current Assets Q1 2026 · Dec 31, 2025 $108.77M
Total Assets Q1 2026 · Mar 31, 2026 $258.39M
Total Assets Q1 2026 · Dec 31, 2025 $115.87M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.69
Eps Diluted Q1 2026 · Mar 31, 2025 −$3.96
Eps Basic Q1 2026 · Mar 31, 2026 −$0.69
Eps Basic Q1 2026 · Mar 31, 2025 −$3.96
Sga Expense Q1 2026 · Mar 31, 2026 $6.87M
Sga Expense Q1 2026 · Mar 31, 2025 $1.37M
Rd Expense Q1 2026 · Mar 31, 2026 $8.54M
Rd Expense Q1 2026 · Mar 31, 2025 $6.05M
Net Income Q1 2026 · Mar 31, 2026 −$13.82M
Net Income Q1 2026 · Mar 31, 2025 −$8.82M
Operating Income Q1 2026 · Mar 31, 2026 −$15.41M
Operating Income Q1 2026 · Mar 31, 2025 −$7.42M